We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




MIT Outlicenses Biosensor Technology

By HospiMedica staff writers
Posted on 11 Dec 2003
New biosensor technology that can be used for extremely rapid testing of analytes, developed by researchers at the Massachusetts Institute of Technology (Cambridge, MA, USA), has been licensed to Innovative Biosensors, Inc. More...
(Gaithersburg, MD, USA).

Called Canary, the technology uses cells of the immune system that have been engineered to express recombinant antibodies specific to the antigen of interest as well as a protein-based emitter molecule in the cell's cytosol. The binding of the antigen to the engineered antibody on the cell's surface results in light emission, detectable in a sensitive and rapid fashion by a small optical detection device. This approach allows for rapid testing with previously unseen levels of sensitivity and specificity.

The license gives Innovative Biosensors exclusive rights to use the technology in the fields of human and animal clinical diagnostics, food testing, and sales to the life science research market. The license also makes Innovative Biosensors the only company allowed to develop, manufacture, and sell instruments and kits using the cell-based biosensor technology in these fields. Innovative Biosensors is developing novel technologies for the rapid detection of pathogens.

"We are extremely delighted to have obtained rights to this novel and revolutionary technology and will move quickly to commercialize much-needed rapid, sensitive, and specific assays for the detection of infectious organisms,” said Joe Hernandez, founder and CEO of Innovative Biosensors.




Related Links:
MIT
Innovative Biosensors

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Portable POCT Blood Gas Analyzer
BD100
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Adobe Stock

Blood Biomarkers Help Assess Growth Risks During Steroid Treatment in Duchenne Muscular Dystrophy

Children with Duchenne muscular dystrophy (DMD) commonly receive long-term corticosteroids to slow disease progression, but these drugs can impair linear growth and weaken bone. Understanding how specific... Read more

Molecular Diagnostics

view channel
Image: The Xpert Hemorrhagic Fever Panel test runs on Cepheid’s GeneXpert Dx systems (Photo courtesy of Cepheid)

WHO Emergency Listing Supports Rapid Molecular Testing for Ebola Outbreak Response

The Democratic Republic of the Congo is confronting an Ebola Bundibugyo outbreak that the World Health Organization (WHO) designated a Public Health Emergency of International Concern on May 17, 2026.... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification

Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.